🚀 VC round data is live in beta, check it out!
Puma Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Puma Biotechnology and similar public comparables like Newron Pharmaceuticals, Autolus Therapeutics, PureTech Health, CytoDyn and more.
Puma Biotechnology Overview
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Founded
2007
HQ
Employees
172
Website
Sectors
Financials (LTM)
EV
$327M
Puma Biotechnology Financials
Puma Biotechnology reported last 12-month revenue of $208M.
In the same LTM period, Puma Biotechnology generated $152M in gross profit and $26M in net income.
Revenue (LTM)
Puma Biotechnology P&L
In the most recent fiscal year, Puma Biotechnology reported revenue of $228M and EBITDA of $53M.
Puma Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $208M | XXX | $228M | XXX | XXX | XXX |
| Gross Profit | $152M | XXX | $170M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | — | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $26M | XXX | $31M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Puma Biotechnology Stock Performance
Puma Biotechnology has current market cap of $396M, and enterprise value of $327M.
Market Cap Evolution
Puma Biotechnology's stock price is $7.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $327M | $396M | -0.4% | XXX | XXX | XXX | $0.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPuma Biotechnology Valuation Multiples
Puma Biotechnology trades at 1.6x EV/Revenue multiple, and 6.1x EV/EBITDA.
EV / Revenue (LTM)
Puma Biotechnology Financial Valuation Multiples
As of April 11, 2026, Puma Biotechnology has market cap of $396M and EV of $327M.
Equity research analysts estimate Puma Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Puma Biotechnology has a P/E ratio of 15.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $396M | XXX | $396M | XXX | XXX | XXX |
| EV (current) | $327M | XXX | $327M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | 9.8x | XXX | 8.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | 1.9x | XXX | XXX | XXX |
| P/E | 15.2x | XXX | 12.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Puma Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Puma Biotechnology Margins & Growth Rates
Puma Biotechnology's revenue in the last 12 month grew by 5%.
Puma Biotechnology's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.8M for the same period.
Puma Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 31% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 31% | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Puma Biotechnology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Newron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| CytoDyn | XXX | XXX | XXX | XXX | XXX | XXX |
| Replimune Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Puma Biotechnology M&A Activity
Puma Biotechnology acquired XXX companies to date.
Last acquisition by Puma Biotechnology was on XXXXXXXX, XXXXX. Puma Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Puma Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPuma Biotechnology Investment Activity
Puma Biotechnology invested in XXX companies to date.
Puma Biotechnology made its latest investment on XXXXXXXX, XXXXX. Puma Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Puma Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Puma Biotechnology
| When was Puma Biotechnology founded? | Puma Biotechnology was founded in 2007. |
| Where is Puma Biotechnology headquartered? | Puma Biotechnology is headquartered in United States. |
| How many employees does Puma Biotechnology have? | As of today, Puma Biotechnology has over 172 employees. |
| Who is the CEO of Puma Biotechnology? | Puma Biotechnology's CEO is Alan H. Auerbach. |
| Is Puma Biotechnology publicly listed? | Yes, Puma Biotechnology is a public company listed on Nasdaq. |
| What is the stock symbol of Puma Biotechnology? | Puma Biotechnology trades under PBYI ticker. |
| When did Puma Biotechnology go public? | Puma Biotechnology went public in 2012. |
| Who are competitors of Puma Biotechnology? | Puma Biotechnology main competitors are Newron Pharmaceuticals, Autolus Therapeutics, PureTech Health, CytoDyn. |
| What is the current market cap of Puma Biotechnology? | Puma Biotechnology's current market cap is $396M. |
| What is the current revenue of Puma Biotechnology? | Puma Biotechnology's last 12 months revenue is $208M. |
| What is the current revenue growth of Puma Biotechnology? | Puma Biotechnology revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Puma Biotechnology? | Current revenue multiple of Puma Biotechnology is 1.6x. |
| Is Puma Biotechnology profitable? | Yes, Puma Biotechnology is net-income-positive (as of the last 12 months). |
| What is the current net income of Puma Biotechnology? | Puma Biotechnology's last 12 months net income is $26M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.